Lysyl Oxidase, Semaphorin 7a and Semaphorin 3a in Patients With Systemic Sclerosis

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01943968

Enrollment

Registered

2013-09-17

Start date

2013-12-31

Completion date

2014-06-30

Last updated

2013-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic Sclerosis

Brief summary

The aim of our study is to find a biomarker for fibrosis or vasculopathy in systemic sclerosis. We will evaluate a possible correlation between semaphorin 7a, semaphorin 3a and lysyl oxidase and fibrosis (lung and skin) or vasculopathy in patients with systemic sclerosis. The results obtained may help us diagnose these complications of systemic sclerosis and hopefully even monitor patient treatment.

Interventions

OTHERBlood test

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Systemic Sclerosis Patients * Written consent to participation in study

Exclusion criteria

* Serious active medical condition * Other autoimmune rheumatic disease * Current or past allergic/inflammatory reaction * Liver disease * Pregnant or breastfeeding * Illegal drug or alcohol abuse

Design outcomes

Primary

Measure	Time frame	Description
Fibrin Enzyme Levels in Blood	Six months	Patients will undergo blood tests before study and after six months to determine levels of lysyl oxidase, semaphorin 7a and 3a and thus determine severity of the disease (systemic sclerosis).

Countries

Israel

Contacts

Primary ContactKarina Zilber, MD

karinazilber@gmail.com972-54-7870716

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026